Andersch-Björkman Ylva, Micu Emanuela, Seifert Oliver, Lonne-Rahm Sol-Britt, Gillstedt Martin, Osmancevic Amra
Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
J Dermatol. 2023 Nov;50(11):1401-1414. doi: 10.1111/1346-8138.16917. Epub 2023 Aug 31.
The objective of this study was to evaluate emotions of depression and anxiety in psoriatic patients that due to insufficient response to tumor necrosis factor-alpha inhibition (TNF-α), underwent a treatment switch from TNF-α to interleukin 17 inhibition using brodalumab. The Self-rated Montgomery-Asberg Depression Rating Scale and the Hospital Anxiety and Depression Scale were used to assess depression and anxiety. A total of 20 patients with psoriasis were enrolled in the study. They were monitored for a period of 3 months following the transition to brodalumab treatment. The results showed a significant improvement in both the Psoriasis Area and Severity Index as well as symptoms of depression; anxiety symptoms showed a reduction, though not statistically significant. Perhaps of more interest, the positive effects on depression and anxiety seem to be independent of the reduction in skin related psoriatic lesions. These findings highlight the importance of addressing depressive and anxiety symptoms, together with psoriasis severity and quality of life, when managing patients with psoriasis.
本研究的目的是评估银屑病患者中因肿瘤坏死因子-α抑制（TNF-α）反应不足而从TNF-α转换为使用布罗达单抗进行白细胞介素17抑制治疗的抑郁和焦虑情绪。使用自评蒙哥马利-阿斯伯格抑郁评定量表和医院焦虑抑郁量表来评估抑郁和焦虑。共有20例银屑病患者纳入本研究。在转换为布罗达单抗治疗后的3个月内对他们进行监测。结果显示，银屑病面积和严重程度指数以及抑郁症状均有显著改善；焦虑症状有所减轻，尽管无统计学意义。也许更值得关注的是，对抑郁和焦虑的积极影响似乎与皮肤相关银屑病皮损的减少无关。这些发现凸显了在管理银屑病患者时，处理抑郁和焦虑症状以及银屑病严重程度和生活质量的重要性。
